Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is the binding of the monoclonal antibody trastuzumab conjugated to emtansine, a highly cytotoxic agent, which is selectively transported by trastuzumab to cancer cells expressing the HER2 gene. Indicated for the treatment of unresectable or metastatic HER2-positive locally advanced HER2-positive breast cancer who have previously received trastuzumab and a taxane separately or in combination. Intravenous administration in a 1-3 week schedule.
At the date of the last update, we found no published data on its excretion in breast milk.
Although trastuzumab, due to its very high molecular weight and lack of intestinal absorption, could be compatible with breastfeeding, emtansine (there is an average of 3.5 molecules of emtansine for every molecule of trastuzumab) is of low molecular weight (LactMed) and could be excreted in breast milk.
t.
See below the information of this related product: